Spruce Biosciences presents data on TA-ERT for Sanfilippo Syndrome Type B treatment.

Spruce Biosciences has presented long-term data at the 22nd Annual WORLDSymposium, highlighting the potential of tralesinidase alfa enzyme replacement therapy as a disease-modifying treatment for Sanfilippo Syndrome Type B (MPS IIIB). The treatment demonstrated rapid and durable normalization of cerebral spinal fluid heparan sulfate non-reducing end and stabilized cognitive and non-cognitive outcomes for over six years. The safety profile was consistent with intracerebroventricular administration, with over 6,000 doses administered over six years.